ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Acerta Pharma BV
Paolo Ghia; Andrzej Pluta; Malgorzata Wach; Daniel Lysak; Tomas Kozak; Martin Simkovic; Polina Kaplan; Iryna Kraychok; Arpad Illes; Javier de la Serna; Sean Dolan; Phillip Campbell; Gerardo Musuraca; Abraham Jacob; Eric Avery; Jae Hoon Lee; Wei Liang; Priti Patel; Cheng Quah; Wojciech Jurczak